Health Catalyst, Inc. (NASDAQ:HCAT) Shares Sold by Jacobs Levy Equity Management Inc.

Jacobs Levy Equity Management Inc. cut its position in Health Catalyst, Inc. (NASDAQ:HCAT - Free Report) by 86.0% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 112,165 shares of the company's stock after selling 688,905 shares during the period. Jacobs Levy Equity Management Inc. owned about 0.18% of Health Catalyst worth $913,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Price T Rowe Associates Inc. MD grew its holdings in shares of Health Catalyst by 6.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 49,746 shares of the company's stock valued at $375,000 after purchasing an additional 2,831 shares during the last quarter. SG Americas Securities LLC purchased a new stake in shares of Health Catalyst during the 2nd quarter valued at approximately $187,000. Nisa Investment Advisors LLC grew its stake in Health Catalyst by 461.0% during the second quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company's stock valued at $41,000 after acquiring an additional 5,232 shares in the last quarter. Perfromance Wealth Partners LLC purchased a new position in Health Catalyst during the second quarter worth about $64,000. Finally, Principal Financial Group Inc. raised its stake in Health Catalyst by 6.9% in the second quarter. Principal Financial Group Inc. now owns 29,469 shares of the company's stock valued at $188,000 after purchasing an additional 1,907 shares in the last quarter. 85.00% of the stock is currently owned by institutional investors and hedge funds.

Health Catalyst Price Performance

NASDAQ HCAT traded up $0.15 during trading on Monday, hitting $8.50. 234,398 shares of the stock traded hands, compared to its average volume of 564,410. The company has a market capitalization of $517.21 million, a P/E ratio of -6.34 and a beta of 1.31. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. The firm has a 50-day simple moving average of $8.13 and a 200-day simple moving average of $7.38. Health Catalyst, Inc. has a 12-month low of $5.42 and a 12-month high of $11.41.

Health Catalyst (NASDAQ:HCAT - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). The firm had revenue of $76.40 million for the quarter, compared to analysts' expectations of $76.27 million. Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The company's revenue for the quarter was up 3.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.22) earnings per share. As a group, analysts predict that Health Catalyst, Inc. will post -0.33 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently weighed in on the stock. Cantor Fitzgerald reiterated an "overweight" rating and issued a $16.00 price target on shares of Health Catalyst in a report on Friday, October 4th. Piper Sandler reissued an "overweight" rating and issued a $12.00 target price (up from $11.00) on shares of Health Catalyst in a report on Tuesday, November 26th. Royal Bank of Canada lifted their target price on Health Catalyst from $8.00 to $9.00 and gave the stock a "sector perform" rating in a report on Thursday, November 7th. Stephens boosted their price target on shares of Health Catalyst from $7.00 to $9.00 and gave the company an "equal weight" rating in a report on Thursday, November 14th. Finally, JPMorgan Chase & Co. raised their price target on Health Catalyst from $10.00 to $13.00 and gave the stock an "overweight" rating in a report on Wednesday, September 4th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat.com, Health Catalyst currently has a consensus rating of "Moderate Buy" and a consensus target price of $11.79.

Insider Transactions at Health Catalyst

In related news, insider Kevin Lee Freeman sold 7,500 shares of Health Catalyst stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $8.94, for a total transaction of $67,050.00. Following the completion of the transaction, the insider now directly owns 236,950 shares in the company, valued at approximately $2,118,333. This trade represents a 3.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Daniel Lesueur sold 5,209 shares of the company's stock in a transaction dated Thursday, October 3rd. The stock was sold at an average price of $7.68, for a total value of $40,005.12. Following the completion of the transaction, the chief operating officer now directly owns 134,899 shares of the company's stock, valued at $1,036,024.32. The trade was a 3.72 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 20,566 shares of company stock valued at $169,130. Corporate insiders own 2.50% of the company's stock.

Health Catalyst Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.